Related references
Note: Only part of the references are listed.Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life
Nichola Cooper et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Octavio Morante-Palacios et al.
TRENDS IN IMMUNOLOGY (2021)
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish et al.
JOURNAL OF IMMUNOLOGY (2021)
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update
Jose Carlos Jaime-Perez et al.
BLOOD REVIEWS (2021)
Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules
Genevieve Marcoux et al.
BLOOD (2021)
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
Etienne Crickx et al.
HAEMATOLOGICA (2021)
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia Beyond Ibrutinib
Masa Lasica et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia
Charlotte A. Bradbury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments
Sylvain Audia et al.
HEMASPHERE (2021)
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations
F. Zaja et al.
BLOOD REVIEWS (2020)
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
Adrian C. Newland et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic
Sue Pavord et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
An update on the pathophysiology of immune thrombocytopenia
John W. Semple et al.
CURRENT OPINION IN HEMATOLOGY (2020)
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Tadeusz Robak et al.
BLOOD ADVANCES (2020)
Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia
Catherine M. Broome et al.
BLOOD (2020)
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
Abraham Z. Cheloff et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Thrombopoietin receptor agonists: ten years later
Waleed Ghanima et al.
HAEMATOLOGICA (2019)
Next-generation Fc receptor-targeting biologics for autoimmune diseases
Adrian W. Zuercher et al.
AUTOIMMUNITY REVIEWS (2019)
Serum Complement Levels in Immune Thrombocytopenia: Characterization and Relation to Clinical Features
Abraham Z. Cheloff et al.
BLOOD (2019)
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
James B. Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
Hanny Al-Samkari et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD ADVANCES (2019)
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
James Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Emerging Concepts in Immune Thrombocytopenia
Maurice Swinkels et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Wojciech Jurczak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Peter Ulrichts et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Affinity Maturation Is Impaired by Natural Killer Cell Suppression of Germinal Centers
Carolyn E. Rydyznski et al.
CELL REPORTS (2018)
The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases
Maria Grazia Roncarolo et al.
IMMUNITY (2018)
Activity of eltrombopag in severe aplastic anemia
Phillip Scheinberg
BLOOD ADVANCES (2018)
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Anne Zufferey et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets
Anne Zufferey et al.
BLOOD ADVANCES (2017)
NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia
M. Ebbo et al.
CLINICAL IMMUNOLOGY (2017)
Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells
Rukhsana Aslam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia
Yu Hou et al.
BLOOD (2016)
NK cells and interferons
Rossella Paolini et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection
Kevin D. Cook et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2015)
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
Shaan Chugh et al.
LANCET HAEMATOLOGY (2015)
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
Tomas Jose Gonzalez-Lopez et al.
PLATELETS (2015)
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia
Lucia Catani et al.
ANNALS OF HEMATOLOGY (2013)
The biology of thrombopoietin and thrombopoietin receptor agonists
David J. Kuter
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
Bahareh Ghadaki et al.
TRANSFUSION (2013)
Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia
Shu-qian Xu et al.
ANNALS OF HEMATOLOGY (2012)
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
Scott M. Hayter et al.
AUTOIMMUNITY REVIEWS (2012)
Defective regulatory B-cell compartment in patients with immune thrombocytopenia
Xiaojuan Li et al.
BLOOD (2012)
Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)
Abderrahim Najaoui et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia
Akio Saito et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Platelets Present Antigen in the Context of MHC Class I
Lesley M. Chapman et al.
JOURNAL OF IMMUNOLOGY (2012)
Reduced Expression of Transforming Growth Factor-β1 and Correlated Elevation of Interleukin-17 and Interferon-γ in Pediatric Patients with Chronic Primary Immune Thrombocytopenia (ITP)
Jiaan-Der Wang et al.
PEDIATRIC BLOOD & CANCER (2011)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents
Weili Bao et al.
BLOOD (2010)
Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
Steven L. Highfill et al.
BLOOD (2010)
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
David J. Kuter
ANNUAL REVIEW OF MEDICINE (2009)
Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
Connie L. Erickson-Miller et al.
STEM CELLS (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura
David J. Kuter
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes
Lucia Catani et al.
EXPERIMENTAL HEMATOLOGY (2006)
Human platelets target dendritic cell differentiation and production of proinflammatory cytokines
K Kissel et al.
TRANSFUSION (2006)
Management of immune thrombocytopenic purpura in adults
R Stasi et al.
MAYO CLINIC PROCEEDINGS (2004)
Brief report - Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response
FP Panitsas et al.
BLOOD (2004)
Macrophage migration inhibitory factor: A regulator of innate immunity
T Calandra et al.
NATURE REVIEWS IMMUNOLOGY (2003)
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
B Olsson et al.
NATURE MEDICINE (2003)
Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages
A Denys et al.
JOURNAL OF IMMUNOLOGY (2002)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Reduced transforming growth factor-beta 1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura
PO Andersson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura
PO Andersson et al.
ANNALS OF HEMATOLOGY (2000)
Share Paper
